1JK Stock Overview A commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Apellis Pharmaceuticals, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Apellis Pharmaceuticals Historical stock prices Current Share Price US$28.49 52 Week High US$65.50 52 Week Low US$23.68 Beta 0.94 1 Month Change -8.75% 3 Month Change 14.97% 1 Year Change -52.92% 3 Year Change -18.61% 5 Year Change -24.24% Change since IPO 29.74%
Recent News & Updates
Apellis Pharmaceuticals, Inc. Announces Executive Changes Jan 14
Apellis Pharmaceuticals Appoints Keli Walbert to the Board of Directors Jan 10
Third quarter 2024 earnings released: US$0.46 loss per share (vs US$1.17 loss in 3Q 2023) Nov 05
Sobi and Apellis Pharmaceuticals, Inc. Announces Detailed Data from the Phase 3 Valiant Study Oct 28
Apellis Pharmaceuticals, Inc. Presents Positive Results from the Phase 3 VALIANT Study at Kidney Week Oct 27
Forecast breakeven date pushed back to 2026 Oct 14 See more updates
Apellis Pharmaceuticals, Inc. Announces Executive Changes Jan 14
Apellis Pharmaceuticals Appoints Keli Walbert to the Board of Directors Jan 10
Third quarter 2024 earnings released: US$0.46 loss per share (vs US$1.17 loss in 3Q 2023) Nov 05
Sobi and Apellis Pharmaceuticals, Inc. Announces Detailed Data from the Phase 3 Valiant Study Oct 28
Apellis Pharmaceuticals, Inc. Presents Positive Results from the Phase 3 VALIANT Study at Kidney Week Oct 27
Forecast breakeven date pushed back to 2026 Oct 14
Sobi and Apellis Announce Positive Topline Results from Phase 3 Valiant Study of Pegcetacoplan in C3G and Primary IC-MPGN Aug 08
Forecast to breakeven in 2025 Aug 04
Second quarter 2024 earnings released: US$0.30 loss per share (vs US$1.02 loss in 2Q 2023) Aug 02
Apellis Pharmaceuticals, Inc. Announces Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress May 25
First quarter 2024 earnings released: US$0.54 loss per share (vs US$1.56 loss in 1Q 2023) May 07
Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024 Apr 28
Apellis Announces Pegcetacoplan MAA Review Reset to Initial Assessment by European Medicines Agency Apr 27
Chief Technical Operations Officer recently sold €590k worth of stock Mar 15
Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024 Mar 11
Full year 2023 earnings released: US$4.45 loss per share (vs US$6.15 loss in FY 2022) Feb 28
Apellis Pharmaceuticals, Inc. Announces Negative CHMP Opinion for Pegcetacoplan for Ga in the European Union and Plans to Seek Re-Examination of Application Jan 26
Apellis Pharmaceuticals, Inc. Appoints Adam Townsend as Chief Operating Officer Jan 23
Co-Founder recently sold €482k worth of stock Jan 18
Apellis Pharmaceuticals, Inc. Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union Dec 15
Apellis Pharmaceuticals, Inc. and Sobi Presents Post Hoc Data that Reinforce the Long-Term Efficacy and Safety of EMPAVELI Dec 11
Insufficient new directors Nov 30 Apellis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $300 million. Nov 02
Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G
Apellis Pharmaceuticals, Inc. Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration Oct 05
Apellis Pharmaceuticals, Inc. Receives Permanent J-Code (J2781) for SYFOVRE® (Pegcetacoplan Injection), Effective October 1, 2023 Sep 26
Levi & Korsinsky, LLP Notifies Investors in Apellis Pharmaceuticals, Inc. of Class Action Securities Lawsuit Sep 22 Apellis Pharmaceuticals, Inc. Announces Corporate Restructuring to Drive Growth of SYFOVRE and EMPAVELI Aug 30
Apellis Pharmaceuticals, Inc. Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE (Pegcetacoplan Injection) Aug 23
Kessler Topaz Meltzer & Check, LLP and Bernstein Litowitz Berger & Grossmann LLP Files Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc Aug 03
No longer forecast to breakeven Aug 01
Second quarter 2023 earnings released: US$1.02 loss per share (vs US$1.46 loss in 2Q 2022) Jul 31 Apellis Pharmaceuticals, Inc. Provides Update on Review of Rare Safety Events with SYFOVRE® for Geographic Atrophy Jul 30
Insufficient new directors May 01
FDA Approves Syfovre (Pegcetacoplan Injection) as the First and Only Treatment for Geographic Atrophy (GA) Feb 18
Apellis Appoints Retina Specialist Dr. Caroline Baumal as Chief Medical Officer Jan 06
Forecast to breakeven in 2025 Dec 31
Apellis Announces FDA Acceptance of NDA Amendment and New PDUFA Date of February 26, 2023 for Pegcetacoplan for Geographic Atrophy (GA) Nov 19
Insufficient new directors Nov 16 Apellis Pharmaceuticals, Inc. Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan NDA for Geographic Atrophy
Apellis Pharmaceuticals, Inc. Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting Oct 01
Apellis Pharmaceuticals, Inc. Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies in Geographic Atrophy Aug 25
Apellis Pharmaceuticals, Inc. Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of Geographic Atrophy Jul 20
Apellis Pharmaceuticals, Inc. Announces Five Oral Presentations in Geographic Atrophy Highlighted at the ASRS Annual Scientific Meeting Jul 16
Insider recently sold €116k worth of stock Jun 24 Apellis Pharmaceuticals, Inc. and Sobi(R) Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI (pegcetacoplan) for PNH at EHA 2022 Congress
Apellis Pharmaceuticals, Inc. and Sobi Announces First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need Jun 08
Apellis Announces Submission of New Drug Application to the FDA for Pegcetacoplan for Geographic Atrophy Jun 02
No longer forecast to breakeven May 06
Apellis Pharmaceuticals, Inc. Announces Appointment of Peter Hillmen as Head of Hematology Engagement, Effective May 23, 2022 May 05
Apellis Pharmaceuticals, Inc. Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy at ARVO Annual Meeting May 03
Insufficient new directors Apr 27
Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 01, 2022 Apr 21
No longer forecast to breakeven Mar 04
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 02
General Counsel recently sold €51k worth of stock Jan 05
Forecast to breakeven in 2024 Jan 01 Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Announce EU Approval of Aspaveli® (Pegcetacoplan) for Treatment of PNH
Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (publ) Report Empaveli™ Demonstrated Sustained Normalization of Clinical Measures in a Broad PNH Patient Population Dec 15
Apellis Announces Results from Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA) and Plans to Submit NDA to FDA in the First Half of 2022 Sep 10
Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB (Publ) Report Positive Top-Line Results from the Phase 3 Prince Study of EMPAVELI™ (pegcetacoplan) in Treatment-naïve Patients with PNH May 26
Apellis Announces U.S. Food and Drug Administration (Fda) Approval of Empaveli™ (Pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH) May 15
ApApellis Pharmaceuticals, Inc. to Present Long-Term Pegcetacoplan Data in PNH at the European Hematology Association Virtual Congress May 13
The NEJM Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH Mar 19
Apellis Pharmaceuticals, Inc. Provides Update on APL-9 for Severe COVID-19 Mar 05
New 90-day high: €46.60 Jan 11
Apellis Pharmaceuticals, Inc. Enters into A Commercial Supply Agreement with Bachem Americas, Inc Jan 05
New 90-day high: €45.40 Dec 24
Swedish Orphan Biovitrum AB and Apellis Pharmaceuticals Inc. Reports Positive Top-Line Results At 48 Weeks from the Phase 3 Pegasus Study of Pegcetacoplan in PNH Dec 11
New 90-day high: €41.40 Dec 07
Sobi and Apellis Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan Nov 20
Apellis Pharmaceuticals Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of PNH Nov 18
New 90-day high: €31.20 Nov 05
Apellis, Enters Strategic Collaboration with Sobi to Develop and Commercialize Pegcetacoplan in Hematologic Indications Outside the US Oct 29
Apellis Pharmaceuticals Announces 18-Month Data from Phase 1B Study of Pegcetacoplan in Patients with Geographic Atrophy Oct 20
Apellis Pharmaceuticals, Inc. Announces Observational Study Results That Found A Correlation Between Covid-19 Severity and Complement Overactivation Oct 16
Apellis Pharmaceuticals, Inc. to Present Positive Results from the Phase 2 Discovery Study of Pegcetacoplan in C3 Glomerulopathy (C3g) At Asn Kidney Week Oct 11
New 90-day high: €30.00 Oct 08
Apellis Initiates Registrational Programs of Pegcetacoplan in Patients with C3G / IC-MPGN and ALS, Rare Diseases with High Unmet Need Oct 06
Apellis Pharmaceuticals, Inc. Announces the Results of a Post Hoc Analysis of the Phase 2 Filly Study Investigating Intravitreal Pegcetacoplan for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration Oct 04
Apellis Pharmaceuticals, Inc. Announces Late-Breaking Presentation of Targeted C3 Therapy Pegcetacoplan in Patients with Geographic Atrophy (GA) at EURETINA 2020 Sep 22
New 90-day low - €25.00 Jul 24 Shareholder Returns 1JK DE Biotechs DE Market 7D 3.4% -3.0% 2.3% 1Y -52.9% -5.3% 11.9%
See full shareholder returns
Return vs Market: 1JK underperformed the German Market which returned 11.9% over the past year.
Price Volatility Is 1JK's price volatile compared to industry and market? 1JK volatility 1JK Average Weekly Movement 9.1% Biotechs Industry Average Movement 6.1% Market Average Movement 4.8% 10% most volatile stocks in DE Market 10.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 1JK's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1JK's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development.
Show more Apellis Pharmaceuticals, Inc. Fundamentals Summary How do Apellis Pharmaceuticals's earnings and revenue compare to its market cap? 1JK fundamental statistics Market cap €3.63b Earnings (TTM ) -€240.07m Revenue (TTM ) €686.54m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 1JK income statement (TTM ) Revenue US$715.22m Cost of Revenue US$417.28m Gross Profit US$297.94m Other Expenses US$548.04m Earnings -US$250.10m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -2.01 Gross Margin 41.66% Net Profit Margin -34.97% Debt/Equity Ratio 190.7%
How did 1JK perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/23 01:12 End of Day Share Price 2025/01/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Apellis Pharmaceuticals, Inc. is covered by 34 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Colleen Kusy Baird Michael Ulz Baird Ishan Majumdar Baptista Research
Show 31 more analysts 
